First, we demonstrated that ISG15 induced ccRCC progression via the IL-6/JAK2/STAT3 pathway; however, the precise mechanism by which activated STAT3 affects ccRCC phenotypic changes is unknown. This evidence concerns the gene IL6 and nonpapillary renal cell carcinoma.